Skip to content

Parallel In Vivo Screening of Gene Knockout and Activation in the Mouse Mammary Gland.

Jul 2026 · Journal of Visualized Experiments · Vol 233 · 0 citations
Medicine

TL;DR

A simple and versatile intraductal injection strategy that enables efficient and rapid functional genomic screening in the mouse mammary gland, by generating tens of thousands of discrete epithelial clones is described.

Abstract

Forward genetics screens are routinely employed to perturb thousands of genetic elements in a pooled fashion with the goal of producing large-scale genotype-to-phenotype maps. While often carried out in cell culture systems, accumulating evidence supports that in vivo screens have the power to unveil new biology that cannot be recapitulated in vitro. However, the widespread application of this approach has been limited by two major challenges: a predominant focus on loss-of-function perturbations rather than gene activation and the significant technical hurdles of delivering complex genetic libraries to specific tissues in vivo. To overcome these challenges, we describe a simple and versatile intraductal injection strategy that enables efficient and rapid functional genomic screening in the mouse mammary gland, by generating tens of thousands of discrete epithelial clones. Furthermore, we provide all the details necessary for library generation, intraductal injection, screen deconvolution, and analysis of CRISPR-Knockout and Activation libraries for comprehensive in vivo screens. Using these tools, which we termed CRISPR-KOALA (Knockout and Activation Linked Assay), we have identified new tumor suppressors and oncogenes within the coding and non-coding genome in pooled libraries ranging from 46 loci to one-fifth of the genome. Importantly, this approach and analysis can be applied to other organs to study the biological function of any gene during homeostasis or disease.

View source

Similar papers

Open access Sep 2026

A high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways ex vivo and in vivo

Partita, a next-generation mouse whole-genome CRISPRa sgRNA platform, designed for unparalleled efficiency in gene activation studies, is introduced, unlocking new avenues for functional genomics and expanding the toolkit for discovering key drivers of biological processes across diverse research fields.

Sarah T. Diepstraten, Yexuan Deng, Margaret A. Potts et al. · 0 citations
Review Open access Sep 2026

Large serine recombinase-mediated gene insertion for high-throughput screens: advantages, design principles, and applications

Abstract High-throughput functional assays, such as multiplexed assays of variant effect (MAVE), increasingly demand stable, precise integration of large DNA libraries into mammalian genomes. While CRISPR-based technologies excel at localized, small-scale edits, they are constrained by payload size limits, heterogeneou...

A. Martella, Kenneth A. Matreyek, D. Fisher · 0 citations
Open access Aug 2026

Perturb-ME: Scalable mechanism discovery from phenotype-enriched genome-wide screens

Perturb-ME, along with agentic interpretation, provide a scalable framework for comprehensive functional discovery from phenotype-enriched genetic screens and combines genome-scale CRISPR screening, phenotype-based enrichment and multimodal single-cell profiling.

Han-Chen Wang, Jiacheng Gu, Chris J. Frangieh et al. · 0 citations
Open access Aug 2026

Genome-wide CRISPR screening identifies cellular factors controlling nonviral genome editing efficiency

To systematically map cellular factors constraining nonviral genome editing, influencing uptake and intracellular trafficking, we develop a genome-wide CRISPR screening platform linking perturbation of 19,114 genes to editing outcomes in human cells. We identify six negative regulators of delivery whose depletion incre...

Shivani Saxena, Meha Kabra, Amr A. Abdeen et al. · 0 citations
Mar 2025

Genome-Wide CRISPR Screening Identifies Cellular Factors Controlling Nonviral Genome Editing Efficiency

A novel genome-wide CRISPR screening strategy that will facilitate the systematic engineering of novel nonviral genome editing delivery methods, where the identified novel gene hits can be further used to increase editing efficiency for other therapeutically relevant cell types.

Shivani Saxena, Meha Kabra, Amr A. Abdeen et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.